Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › R&D spending
Kiniksa Pharmaceuticals International (KNSA) R&D spending by quarter
Kiniksa Pharmaceuticals International's R&D spending was $32.8M in Q3 2026 (third quarter 2026), -20% from Q2 2026. Over the last 7 quarters it ranged from $18.8M (Q2 2025) to $40.9M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $32.8M | -20% | +36% |
| Q2 2026 | $40.9M | +49% | +118% |
| Q1 2026 | $27.5M | -21% | +42% |
| Q4 2025 | $34.6M | +43% | — |
| Q3 2025 | $24.2M | +29% | — |
| Q2 2025 | $18.8M | -3% | — |
| Q1 2025 | $19.3M | — | — |
Q3 2026 at a glance
Kiniksa Pharmaceuticals International, Q3 2026: revenue $286M (+58% year over year), operating margin 19.0%, net earnings $47.3M, operating cash flow $47.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Kiniksa Pharmaceuticals International's R&D spending?
Kiniksa Pharmaceuticals International's R&D spending was $32.8M in Q3 2026 (third quarter 2026), -20% from Q2 2026.
How has Kiniksa Pharmaceuticals International's R&D spending changed?
Over the last 7 quarters it ranged from $18.8M (Q2 2025) to $40.9M (Q2 2026).
Q3 2026 results → · How Kiniksa Pharmaceuticals International makes money →